SOLENO THERAPEUTICS INC (SLNO) Earnings Signals & AI Vibe Check
Cross-checked across multiple AI analysts and grounded in the latest SEC filing.
powered by: earningsVibe.ai
Question:
What is the latest filing signal for SOLENO THERAPEUTICS INC?
Answer:
Based on earningsVibe SuperAnalyst™ synthesis of the latest
10-K, SOLENO THERAPEUTICS INC's filing signal
turned positive.
earningsVibe SuperAnalyst™ Verdict:
TURNED POSITIVE
Signal Performance — Stock Price Since Filing
30-Day Change
-26.73%
from filing date
60-Day Change
Pending
from filing date
Underlying analyst views from Perplexity, Gemini, Claude, and ChatGPT
PERPLEXITY
Turned Positive
GEMINI
Turned Positive
CLAUDE
Turned Positive
CHATGPT
Turned Positive
Unlock the Full Filing Analysis
See full earningsSig™ and risksSig™ analysis across 5,000+ companies
Get Started Free →No credit card required
Question:
What does SOLENO THERAPEUTICS INC actually do?
Answer:
Soleno Therapeutics, Inc. is a biopharmaceutical company focused on developing treatments for rare diseases, notably Prader-Willi syndrome (PWS). Its lead product, VYKAT XR (diazoxide choline) extended-release tablets, received FDA approval in March 2025 for treating hyperphagia in PWS patients aged four and older. VYKAT XR works by activating K ATP channels, aiming to reduce appetite, improve satiety, and impact metabolic processes. The company began recognizing revenue from VYKAT XR sales in the second quarter of 2025. Soleno Therapeutics is headquartered in Redwood City, California, and operates as a single business segment.
Question:
What are SOLENO THERAPEUTICS INC's revenue drivers?
Answer:
Revenue is primarily driven by the sales of VYKAT XR, its lead product for treating hyperphagia in patients with Prader-Willi syndrome.
Cut through noisy SEC filings to find the signal faster
Source-grounded filing intelligence with one-click links back to the filing, so you can move faster and verify everything at the source.
Get Started Free →No credit card required